Plus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM Trial

2 years ago

Biocept’s CNSide™ assay provides a highly sensitive method to assess and quantify tumor cell burden in leptomeningeal metastasis (LM) of…

BridgeBio Pharma Announces Early Positive Data for BBP-812, its Investigational AAV9 Gene Therapy for Canavan Disease

2 years ago

- These results are the first reported demonstration of rapid and robust treatment changes in key disease markers associated with…

BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

2 years ago

MELVILLE, NY., June 22, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage…

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 years ago

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 22, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy…

Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors

2 years ago

BERKELEY HEIGHTS, N.J., June 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a…

Medicenna Reports Fiscal Year 2022 Financial Results and Operational Highlights

2 years ago

--Cash runway extended late into calendar Q2 2023 --Tumor control achieved following MDNA11 treatment in 3 out of 8 patients…

ProMIS Neurosciences Announces Authorization of Series 1 Preferred Shares

2 years ago

TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 22, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or…

ProMIS Neurosciences Announces Filing of Form 10 Registration Statement and Nasdaq Listing Application

2 years ago

TORONTO, Ontario and CAMBRIDGE, Massachusetts , June 22, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS”…

Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa

2 years ago

PITTSBURGH, June 22, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy,…

Tonix Pharmaceuticals Announces Pricing of $30 Million Private Placement of Convertible Redeemable Preferred Stock

2 years ago

CHATHAM, N.J., June 22, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced…